What is it about?
To investigate more effective chemotherapy against hormone refractory prostate cancer (HRPC) with the combination of estramustine (EM), docetaxel, and suramin.
Photo by Quino Al on Unsplash
Why is it important?
Management of this hormone refractory stage of prostate cancer remains a significant challenge to the clinician.
Read the Original
This page is a summary of: Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer, Urologic Oncology Seminars and Original Investigations, March 2005, Elsevier, DOI: 10.1016/j.urolonc.2004.10.003.
You can read the full text:
The following have contributed to this page